Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia - PubMed (original) (raw)
Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia
C Imai et al. Leukemia. 2004 Apr.
Abstract
To develop a therapy for drug-resistant B-lineage acute lymphoblastic leukemia (ALL), we transduced T lymphocytes with anti-CD19 chimeric receptors, consisting of an anti-CD19 single-chain variable domain (reactive with most ALL cases), the hinge and transmembrane domains of CD8alpha, and the signaling domain of CD3zeta. We compared the antileukemic activity mediated by a novel receptor ('anti-CD19-BB-zeta') containing the signaling domain of 4-1BB (CD137; a crucial molecule for T-cell antitumor activity) to that of a receptor lacking costimulatory molecules. Retroviral transduction produced efficient and durable receptor expression in human T cells. Lymphocytes expressing anti-CD19-BB-zeta receptors exerted powerful and specific cytotoxicity against ALL cells, which was superior to that of lymphocytes with receptors lacking 4-1BB. Anti-CD19-BB-zeta lymphocytes were remarkably effective in cocultures with bone marrow mesenchymal cells, and against leukemic cells from patients with drug-resistant ALL: as few as 1% anti-CD19-BB-zeta-transduced T cells eliminated most ALL cells within 5 days. These cells also expanded and produced interleukin-2 in response to ALL cells at much higher rates than those of lymphocytes expressing equivalent receptors lacking 4-1BB. We conclude that anti-CD19 chimeric receptors containing 4-1BB are a powerful new tool for T-cell therapy of B-lineage ALL and other CD19+ B-lymphoid malignancies.
Similar articles
- Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-zeta activating signal.
Marin V, Kakuda H, Dander E, Imai C, Campana D, Biondi A, D'Amico G. Marin V, et al. Exp Hematol. 2007 Sep;35(9):1388-97. doi: 10.1016/j.exphem.2007.05.018. Epub 2007 Jul 25. Exp Hematol. 2007. PMID: 17656004 - Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy.
Marin V, Dander E, Biagi E, Introna M, Fazio G, Biondi A, D'Amico G. Marin V, et al. Exp Hematol. 2006 Sep;34(9):1219-29. doi: 10.1016/j.exphem.2006.05.004. Exp Hematol. 2006. PMID: 16939815 - Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.
Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, Wilson WH, Rosenberg SA. Kochenderfer JN, et al. J Immunother. 2009 Sep;32(7):689-702. doi: 10.1097/CJI.0b013e3181ac6138. J Immunother. 2009. PMID: 19561539 Free PMC article. - Genetic modification of T cells for cancer therapy.
Imai C, Campana D. Imai C, et al. J Biol Regul Homeost Agents. 2004 Jan-Mar;18(1):62-71. J Biol Regul Homeost Agents. 2004. PMID: 15323362 Review. - Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential applications in cancer therapy.
Sica G, Chen L. Sica G, et al. Arch Immunol Ther Exp (Warsz). 1999;47(5):275-9. Arch Immunol Ther Exp (Warsz). 1999. PMID: 10604232 Review.
Cited by
- Several factors that predict the outcome of large B-cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T-cell therapy can be identified before cell administration.
Sýkorová A, Folber F, Polgárová K, Móciková H, Ďuraš J, Steinerová K, Obr A, Heindorfer A, Ladická M, Lukáčová Ľ, Čellárová E, Plameňová I, Belada D, Janíková A, Trněný M, Jančárková T, Procházka V, Vranovský A, Králiková M, Vydra J, Smolej L, Drgoňa Ľ, Sedmina M, Čermáková E, Pytlík R. Sýkorová A, et al. Cancer Med. 2024 Sep;13(17):e70138. doi: 10.1002/cam4.70138. Cancer Med. 2024. PMID: 39248284 Free PMC article. - Fratricide-resistant CD7-CAR T cells in T-ALL.
Oh BLZ, Shimasaki N, Coustan-Smith E, Chan E, Poon L, Lee SHR, Yeap F, Tan LK, Chai LYA, Le Bert N, Tan N, Bertoletti A, Chen SP, Del Bufalo F, Becilli M, Locatelli F, Yeoh AEJ, Campana D. Oh BLZ, et al. Nat Med. 2024 Sep 3. doi: 10.1038/s41591-024-03228-8. Online ahead of print. Nat Med. 2024. PMID: 39227445 - Chick Embryo Chorioallantoic Membrane as a Platform for Assessing the In Vivo Efficacy of Chimeric Antigen Receptor T-cell Therapy in Solid Tumors.
Nipper AJ, Warren EAK, Liao KS, Liu HC, Michikawa C, Porter CE, Wells GA, Villanueva M, Brasil da Costa FH, Veeramachaneni R, Villanueva H, Suzuki M, Sikora AG. Nipper AJ, et al. Immunohorizons. 2024 Aug 1;8(8):598-605. doi: 10.4049/immunohorizons.2400059. Immunohorizons. 2024. PMID: 39225630 Free PMC article. - Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed/refractory multiple myeloma.
Hamadeh IS, Friend R, Mailankody S, Atrash S. Hamadeh IS, et al. Front Oncol. 2024 Aug 8;14:1455464. doi: 10.3389/fonc.2024.1455464. eCollection 2024. Front Oncol. 2024. PMID: 39175472 Free PMC article. Review. - CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma.
Pascual-Pasto G, McIntyre B, Hines MG, Giudice AM, Garcia-Gerique L, Hoffmann J, Mishra P, Matlaga S, Lombardi S, Shraim R, Schürch PM, Yarmarkovich M, Hofmann TJ, Alikarami F, Martinez D, Tsang M, Gil-de-Gómez L, Spear TT, Bernt KM, Wolpaw AJ, Dimitrov DS, Li W, Bosse KR. Pascual-Pasto G, et al. Nat Commun. 2024 Aug 21;15(1):7141. doi: 10.1038/s41467-024-51337-2. Nat Commun. 2024. PMID: 39164224 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials